Global Allergy Shots Market

Allergy Shots Comprehensive Study by Application (Allergic Asthma, Allergic Rhinitis, Eye Allergies (or) Recurring Conjunctivitis, Other), Therapy (Sublingual Immunotherapy, Subcutaneous Immunotherapy, Others), Allergy (Seasonal Allergies (Tree Pollen, Grasses or Weeds), Indoor Allergens (Dust Mites, Cockroaches, Mold), Insect Stings (Bees, Wasps, Hornets)), Distribution Channel (Hospitals (Government, Private), Clinics, Retail Pharmacies), End User (Pediatric, Adults, Geriatric) Players and Region - Global Market Outlook to 2030

Allergy Shots Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Allergy Shots
Allergy shots are vaccines given on a daily basis for 3 to 5 years to prevent or reduce allergic strikes. Immunotherapy is a form of treatment that involves allergy shots. To be healthy, reliable, and efficient, allergy shots must adhere to a strict schedule. Everyone has a different timetable. Patients usually continue with one or two shots a week, although these can vary depending on the number of allergens. To remain on board, many patients prefer to get the injections many days a month. Each allergy shot includes a trace volume of sample or substances that cause you to have an allergic reaction. Allergens are the term for these substances. Allergy shots are relatively superior than its substitutes including Drops, SLIT Tablets in terms of allergy coverage, accuracy and effectiveness in the long run, which is one of the factors responsible for growth in Allergy shots market across the globe.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States & United Kingdom Players will contribute the maximum growth to Global Allergy Shots market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

ALK Abello (Denmark), Stallergenes Greer (United Kingdom), Allergy Therapeutics (United Kingdom), Aimmune Therapeutics (United States), Anergis (Switzerland), Arrayit Corporation (United States), Biomay AG (Austria), HAL Allergy Group (Netherlands), DBV Technologies (France) and Allergopharma GmbH & Co. KG (Dermapharm) (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Jubilant Pharma Holdings Inc. (United States), BioSpace (United States), Omega Laboratories Limited (Canada), Quantum Allergy (Canada), Mylan (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Allergy Shots market by , Application (Allergic Asthma, Allergic Rhinitis, Eye Allergies (or) Recurring Conjunctivitis and Other) and Region.



On the basis of geography, the market of Allergy Shots has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Therapy, the sub-segment i.e. Sublingual Immunotherapy will boost the Allergy Shots market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Allergy, the sub-segment i.e. Seasonal Allergies (Tree Pollen, Grasses or Weeds) will boost the Allergy Shots market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospitals (Government, Private) will boost the Allergy Shots market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Pediatric will boost the Allergy Shots market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Investments in Healthcare Infrastructure

Market Growth Drivers:
Decreasing Dependence on Oral Allergy Medication and Long run Allergy Relief, Therefore Lower Long-Term Costs

Challenges:
High Up-Front Costs and Side Effects and Adverse Reactions

Restraints:
Long Duration Treatment and Risk of Anaphylaxis

Opportunities:
Low Penetration in Emerging Economies Particularly in Asian Region

Market Leaders and their expansionary development strategies
In October, 2020, Nestle Completed its Acquisition of Aimmune Therapeutics (Leading FDA Approved Allergen Products Manufacturer), this Acquisition is part of Nestle’s Plan to Develop Innovative, Science-Based Nutritional Solutions by Combining Aimmune's pharmaceutical Expertise and Infrastructure.
In July 2019, Pfizer Merges Its Off-Patent Drug Business, UpJohn, With Mylan (US-Based Pharma Manufacturer), This Combination Is Aimed to Expand Pfizer’s Portfolio Across Products Including Impotence Drug Viagra, Painkiller Lyrica and the EpiPen Allergy Treatment.
United States, Food and Drug Administration “Allergen Extracts - Injectable” - USDA is the key Regulatory Authority Responsible for Approval, Inspection and Dosage Limitations of Allergy Shots across the United States, FDA limits the usage to licensed prescription holders only. Any New Entrant is Required to have a Regulatory Clearance form FDA. and European Medicines Agency, “Guideline on The Clinical Development of Products for Specific Immunotherapy for The Treatment of Allergic Diseases” - The Guidance Concerns Research Nature, Effectiveness, And Protection for Allergen Drugs Being Formulated for Specific Allergy Immunotherapy (E.g., The Long-Term Treatment and Management of Allergic Conditions Like Rhino-Conjunctivitis and Allergic Reactions to Insect Venoms).

Key Target Audience
Allergy Shots Manufactures, New Entrants and Investors, API Providers, Allergy Shots Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Allergic Asthma
  • Allergic Rhinitis
  • Eye Allergies (or) Recurring Conjunctivitis
  • Other
By Therapy
  • Sublingual Immunotherapy
  • Subcutaneous Immunotherapy
  • Others

By Allergy
  • Seasonal Allergies (Tree Pollen, Grasses or Weeds)
  • Indoor Allergens (Dust Mites, Cockroaches, Mold)
  • Insect Stings (Bees, Wasps, Hornets)

By Distribution Channel
  • Hospitals (Government, Private)
  • Clinics
  • Retail Pharmacies

By End User
  • Pediatric
  • Adults
  • Geriatric

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Decreasing Dependence on Oral Allergy Medication
      • 3.2.2. Long run Allergy Relief, Therefore Lower Long-Term Costs
    • 3.3. Market Challenges
      • 3.3.1. High Up-Front Costs
      • 3.3.2. Side Effects and Adverse Reactions
    • 3.4. Market Trends
      • 3.4.1. Growing Investments in Healthcare Infrastructure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Allergy Shots, by Application, Therapy, Allergy, Distribution Channel, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Allergy Shots (Value)
      • 5.2.1. Global Allergy Shots by: Application (Value)
        • 5.2.1.1. Allergic Asthma
        • 5.2.1.2. Allergic Rhinitis
        • 5.2.1.3. Eye Allergies (or) Recurring Conjunctivitis
        • 5.2.1.4. Other
      • 5.2.2. Global Allergy Shots by: Therapy (Value)
        • 5.2.2.1. Sublingual Immunotherapy
        • 5.2.2.2. Subcutaneous Immunotherapy
        • 5.2.2.3. Others
      • 5.2.3. Global Allergy Shots by: Allergy (Value)
        • 5.2.3.1. Seasonal Allergies (Tree Pollen, Grasses or Weeds)
        • 5.2.3.2. Indoor Allergens (Dust Mites, Cockroaches, Mold)
        • 5.2.3.3. Insect Stings (Bees, Wasps, Hornets)
      • 5.2.4. Global Allergy Shots by: Distribution Channel (Value)
        • 5.2.4.1. Hospitals (Government, Private)
        • 5.2.4.2. Clinics
        • 5.2.4.3. Retail Pharmacies
      • 5.2.5. Global Allergy Shots by: End User (Value)
        • 5.2.5.1. Pediatric
        • 5.2.5.2. Adults
        • 5.2.5.3. Geriatric
      • 5.2.6. Global Allergy Shots Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Allergy Shots: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. ALK Abello (Denmark)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Stallergenes Greer (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Allergy Therapeutics (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Aimmune Therapeutics (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Anergis (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Arrayit Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Biomay AG (Austria)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. HAL Allergy Group (Netherlands)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. DBV Technologies (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Allergopharma GmbH & Co. KG (Dermapharm) (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Allergy Shots Sale, by Application, Therapy, Allergy, Distribution Channel, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Allergy Shots (Value)
      • 7.2.1. Global Allergy Shots by: Application (Value)
        • 7.2.1.1. Allergic Asthma
        • 7.2.1.2. Allergic Rhinitis
        • 7.2.1.3. Eye Allergies (or) Recurring Conjunctivitis
        • 7.2.1.4. Other
      • 7.2.2. Global Allergy Shots by: Therapy (Value)
        • 7.2.2.1. Sublingual Immunotherapy
        • 7.2.2.2. Subcutaneous Immunotherapy
        • 7.2.2.3. Others
      • 7.2.3. Global Allergy Shots by: Allergy (Value)
        • 7.2.3.1. Seasonal Allergies (Tree Pollen, Grasses or Weeds)
        • 7.2.3.2. Indoor Allergens (Dust Mites, Cockroaches, Mold)
        • 7.2.3.3. Insect Stings (Bees, Wasps, Hornets)
      • 7.2.4. Global Allergy Shots by: Distribution Channel (Value)
        • 7.2.4.1. Hospitals (Government, Private)
        • 7.2.4.2. Clinics
        • 7.2.4.3. Retail Pharmacies
      • 7.2.5. Global Allergy Shots by: End User (Value)
        • 7.2.5.1. Pediatric
        • 7.2.5.2. Adults
        • 7.2.5.3. Geriatric
      • 7.2.6. Global Allergy Shots Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Allergy Shots: by Application(USD Million)
  • Table 2. Allergy Shots Allergic Asthma , by Region USD Million (2018-2023)
  • Table 3. Allergy Shots Allergic Rhinitis , by Region USD Million (2018-2023)
  • Table 4. Allergy Shots Eye Allergies (or) Recurring Conjunctivitis , by Region USD Million (2018-2023)
  • Table 5. Allergy Shots Other , by Region USD Million (2018-2023)
  • Table 6. Allergy Shots: by Therapy(USD Million)
  • Table 7. Allergy Shots Sublingual Immunotherapy , by Region USD Million (2018-2023)
  • Table 8. Allergy Shots Subcutaneous Immunotherapy , by Region USD Million (2018-2023)
  • Table 9. Allergy Shots Others , by Region USD Million (2018-2023)
  • Table 10. Allergy Shots: by Allergy(USD Million)
  • Table 11. Allergy Shots Seasonal Allergies (Tree Pollen, Grasses or Weeds) , by Region USD Million (2018-2023)
  • Table 12. Allergy Shots Indoor Allergens (Dust Mites, Cockroaches, Mold) , by Region USD Million (2018-2023)
  • Table 13. Allergy Shots Insect Stings (Bees, Wasps, Hornets) , by Region USD Million (2018-2023)
  • Table 14. Allergy Shots: by Distribution Channel(USD Million)
  • Table 15. Allergy Shots Hospitals (Government, Private) , by Region USD Million (2018-2023)
  • Table 16. Allergy Shots Clinics , by Region USD Million (2018-2023)
  • Table 17. Allergy Shots Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 18. Allergy Shots: by End User(USD Million)
  • Table 19. Allergy Shots Pediatric , by Region USD Million (2018-2023)
  • Table 20. Allergy Shots Adults , by Region USD Million (2018-2023)
  • Table 21. Allergy Shots Geriatric , by Region USD Million (2018-2023)
  • Table 22. South America Allergy Shots, by Country USD Million (2018-2023)
  • Table 23. South America Allergy Shots, by Application USD Million (2018-2023)
  • Table 24. South America Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 25. South America Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 26. South America Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 27. South America Allergy Shots, by End User USD Million (2018-2023)
  • Table 28. Brazil Allergy Shots, by Application USD Million (2018-2023)
  • Table 29. Brazil Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 30. Brazil Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 31. Brazil Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 32. Brazil Allergy Shots, by End User USD Million (2018-2023)
  • Table 33. Argentina Allergy Shots, by Application USD Million (2018-2023)
  • Table 34. Argentina Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 35. Argentina Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 36. Argentina Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 37. Argentina Allergy Shots, by End User USD Million (2018-2023)
  • Table 38. Rest of South America Allergy Shots, by Application USD Million (2018-2023)
  • Table 39. Rest of South America Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 40. Rest of South America Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 41. Rest of South America Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 42. Rest of South America Allergy Shots, by End User USD Million (2018-2023)
  • Table 43. Asia Pacific Allergy Shots, by Country USD Million (2018-2023)
  • Table 44. Asia Pacific Allergy Shots, by Application USD Million (2018-2023)
  • Table 45. Asia Pacific Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 46. Asia Pacific Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 47. Asia Pacific Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 48. Asia Pacific Allergy Shots, by End User USD Million (2018-2023)
  • Table 49. China Allergy Shots, by Application USD Million (2018-2023)
  • Table 50. China Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 51. China Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 52. China Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 53. China Allergy Shots, by End User USD Million (2018-2023)
  • Table 54. Japan Allergy Shots, by Application USD Million (2018-2023)
  • Table 55. Japan Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 56. Japan Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 57. Japan Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 58. Japan Allergy Shots, by End User USD Million (2018-2023)
  • Table 59. India Allergy Shots, by Application USD Million (2018-2023)
  • Table 60. India Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 61. India Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 62. India Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 63. India Allergy Shots, by End User USD Million (2018-2023)
  • Table 64. South Korea Allergy Shots, by Application USD Million (2018-2023)
  • Table 65. South Korea Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 66. South Korea Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 67. South Korea Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 68. South Korea Allergy Shots, by End User USD Million (2018-2023)
  • Table 69. Taiwan Allergy Shots, by Application USD Million (2018-2023)
  • Table 70. Taiwan Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 71. Taiwan Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 72. Taiwan Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 73. Taiwan Allergy Shots, by End User USD Million (2018-2023)
  • Table 74. Australia Allergy Shots, by Application USD Million (2018-2023)
  • Table 75. Australia Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 76. Australia Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 77. Australia Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 78. Australia Allergy Shots, by End User USD Million (2018-2023)
  • Table 79. Rest of Asia-Pacific Allergy Shots, by Application USD Million (2018-2023)
  • Table 80. Rest of Asia-Pacific Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 81. Rest of Asia-Pacific Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 83. Rest of Asia-Pacific Allergy Shots, by End User USD Million (2018-2023)
  • Table 84. Europe Allergy Shots, by Country USD Million (2018-2023)
  • Table 85. Europe Allergy Shots, by Application USD Million (2018-2023)
  • Table 86. Europe Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 87. Europe Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 88. Europe Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 89. Europe Allergy Shots, by End User USD Million (2018-2023)
  • Table 90. Germany Allergy Shots, by Application USD Million (2018-2023)
  • Table 91. Germany Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 92. Germany Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 93. Germany Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 94. Germany Allergy Shots, by End User USD Million (2018-2023)
  • Table 95. France Allergy Shots, by Application USD Million (2018-2023)
  • Table 96. France Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 97. France Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 98. France Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 99. France Allergy Shots, by End User USD Million (2018-2023)
  • Table 100. Italy Allergy Shots, by Application USD Million (2018-2023)
  • Table 101. Italy Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 102. Italy Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 103. Italy Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 104. Italy Allergy Shots, by End User USD Million (2018-2023)
  • Table 105. United Kingdom Allergy Shots, by Application USD Million (2018-2023)
  • Table 106. United Kingdom Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 107. United Kingdom Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 108. United Kingdom Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 109. United Kingdom Allergy Shots, by End User USD Million (2018-2023)
  • Table 110. Netherlands Allergy Shots, by Application USD Million (2018-2023)
  • Table 111. Netherlands Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 112. Netherlands Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 113. Netherlands Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 114. Netherlands Allergy Shots, by End User USD Million (2018-2023)
  • Table 115. Rest of Europe Allergy Shots, by Application USD Million (2018-2023)
  • Table 116. Rest of Europe Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 117. Rest of Europe Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 118. Rest of Europe Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 119. Rest of Europe Allergy Shots, by End User USD Million (2018-2023)
  • Table 120. MEA Allergy Shots, by Country USD Million (2018-2023)
  • Table 121. MEA Allergy Shots, by Application USD Million (2018-2023)
  • Table 122. MEA Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 123. MEA Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 124. MEA Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 125. MEA Allergy Shots, by End User USD Million (2018-2023)
  • Table 126. Middle East Allergy Shots, by Application USD Million (2018-2023)
  • Table 127. Middle East Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 128. Middle East Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 129. Middle East Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 130. Middle East Allergy Shots, by End User USD Million (2018-2023)
  • Table 131. Africa Allergy Shots, by Application USD Million (2018-2023)
  • Table 132. Africa Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 133. Africa Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 134. Africa Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 135. Africa Allergy Shots, by End User USD Million (2018-2023)
  • Table 136. North America Allergy Shots, by Country USD Million (2018-2023)
  • Table 137. North America Allergy Shots, by Application USD Million (2018-2023)
  • Table 138. North America Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 139. North America Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 140. North America Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 141. North America Allergy Shots, by End User USD Million (2018-2023)
  • Table 142. United States Allergy Shots, by Application USD Million (2018-2023)
  • Table 143. United States Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 144. United States Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 145. United States Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 146. United States Allergy Shots, by End User USD Million (2018-2023)
  • Table 147. Canada Allergy Shots, by Application USD Million (2018-2023)
  • Table 148. Canada Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 149. Canada Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 150. Canada Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 151. Canada Allergy Shots, by End User USD Million (2018-2023)
  • Table 152. Mexico Allergy Shots, by Application USD Million (2018-2023)
  • Table 153. Mexico Allergy Shots, by Therapy USD Million (2018-2023)
  • Table 154. Mexico Allergy Shots, by Allergy USD Million (2018-2023)
  • Table 155. Mexico Allergy Shots, by Distribution Channel USD Million (2018-2023)
  • Table 156. Mexico Allergy Shots, by End User USD Million (2018-2023)
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Allergy Shots: by Application(USD Million)
  • Table 168. Allergy Shots Allergic Asthma , by Region USD Million (2025-2030)
  • Table 169. Allergy Shots Allergic Rhinitis , by Region USD Million (2025-2030)
  • Table 170. Allergy Shots Eye Allergies (or) Recurring Conjunctivitis , by Region USD Million (2025-2030)
  • Table 171. Allergy Shots Other , by Region USD Million (2025-2030)
  • Table 172. Allergy Shots: by Therapy(USD Million)
  • Table 173. Allergy Shots Sublingual Immunotherapy , by Region USD Million (2025-2030)
  • Table 174. Allergy Shots Subcutaneous Immunotherapy , by Region USD Million (2025-2030)
  • Table 175. Allergy Shots Others , by Region USD Million (2025-2030)
  • Table 176. Allergy Shots: by Allergy(USD Million)
  • Table 177. Allergy Shots Seasonal Allergies (Tree Pollen, Grasses or Weeds) , by Region USD Million (2025-2030)
  • Table 178. Allergy Shots Indoor Allergens (Dust Mites, Cockroaches, Mold) , by Region USD Million (2025-2030)
  • Table 179. Allergy Shots Insect Stings (Bees, Wasps, Hornets) , by Region USD Million (2025-2030)
  • Table 180. Allergy Shots: by Distribution Channel(USD Million)
  • Table 181. Allergy Shots Hospitals (Government, Private) , by Region USD Million (2025-2030)
  • Table 182. Allergy Shots Clinics , by Region USD Million (2025-2030)
  • Table 183. Allergy Shots Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 184. Allergy Shots: by End User(USD Million)
  • Table 185. Allergy Shots Pediatric , by Region USD Million (2025-2030)
  • Table 186. Allergy Shots Adults , by Region USD Million (2025-2030)
  • Table 187. Allergy Shots Geriatric , by Region USD Million (2025-2030)
  • Table 188. South America Allergy Shots, by Country USD Million (2025-2030)
  • Table 189. South America Allergy Shots, by Application USD Million (2025-2030)
  • Table 190. South America Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 191. South America Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 192. South America Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 193. South America Allergy Shots, by End User USD Million (2025-2030)
  • Table 194. Brazil Allergy Shots, by Application USD Million (2025-2030)
  • Table 195. Brazil Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 196. Brazil Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 197. Brazil Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 198. Brazil Allergy Shots, by End User USD Million (2025-2030)
  • Table 199. Argentina Allergy Shots, by Application USD Million (2025-2030)
  • Table 200. Argentina Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 201. Argentina Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 202. Argentina Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 203. Argentina Allergy Shots, by End User USD Million (2025-2030)
  • Table 204. Rest of South America Allergy Shots, by Application USD Million (2025-2030)
  • Table 205. Rest of South America Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 206. Rest of South America Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 207. Rest of South America Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 208. Rest of South America Allergy Shots, by End User USD Million (2025-2030)
  • Table 209. Asia Pacific Allergy Shots, by Country USD Million (2025-2030)
  • Table 210. Asia Pacific Allergy Shots, by Application USD Million (2025-2030)
  • Table 211. Asia Pacific Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 212. Asia Pacific Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 213. Asia Pacific Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 214. Asia Pacific Allergy Shots, by End User USD Million (2025-2030)
  • Table 215. China Allergy Shots, by Application USD Million (2025-2030)
  • Table 216. China Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 217. China Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 218. China Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 219. China Allergy Shots, by End User USD Million (2025-2030)
  • Table 220. Japan Allergy Shots, by Application USD Million (2025-2030)
  • Table 221. Japan Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 222. Japan Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 223. Japan Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 224. Japan Allergy Shots, by End User USD Million (2025-2030)
  • Table 225. India Allergy Shots, by Application USD Million (2025-2030)
  • Table 226. India Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 227. India Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 228. India Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 229. India Allergy Shots, by End User USD Million (2025-2030)
  • Table 230. South Korea Allergy Shots, by Application USD Million (2025-2030)
  • Table 231. South Korea Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 232. South Korea Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 233. South Korea Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 234. South Korea Allergy Shots, by End User USD Million (2025-2030)
  • Table 235. Taiwan Allergy Shots, by Application USD Million (2025-2030)
  • Table 236. Taiwan Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 237. Taiwan Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 238. Taiwan Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 239. Taiwan Allergy Shots, by End User USD Million (2025-2030)
  • Table 240. Australia Allergy Shots, by Application USD Million (2025-2030)
  • Table 241. Australia Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 242. Australia Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 243. Australia Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 244. Australia Allergy Shots, by End User USD Million (2025-2030)
  • Table 245. Rest of Asia-Pacific Allergy Shots, by Application USD Million (2025-2030)
  • Table 246. Rest of Asia-Pacific Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 247. Rest of Asia-Pacific Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 248. Rest of Asia-Pacific Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 249. Rest of Asia-Pacific Allergy Shots, by End User USD Million (2025-2030)
  • Table 250. Europe Allergy Shots, by Country USD Million (2025-2030)
  • Table 251. Europe Allergy Shots, by Application USD Million (2025-2030)
  • Table 252. Europe Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 253. Europe Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 254. Europe Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 255. Europe Allergy Shots, by End User USD Million (2025-2030)
  • Table 256. Germany Allergy Shots, by Application USD Million (2025-2030)
  • Table 257. Germany Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 258. Germany Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 259. Germany Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 260. Germany Allergy Shots, by End User USD Million (2025-2030)
  • Table 261. France Allergy Shots, by Application USD Million (2025-2030)
  • Table 262. France Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 263. France Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 264. France Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 265. France Allergy Shots, by End User USD Million (2025-2030)
  • Table 266. Italy Allergy Shots, by Application USD Million (2025-2030)
  • Table 267. Italy Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 268. Italy Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 269. Italy Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 270. Italy Allergy Shots, by End User USD Million (2025-2030)
  • Table 271. United Kingdom Allergy Shots, by Application USD Million (2025-2030)
  • Table 272. United Kingdom Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 273. United Kingdom Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 274. United Kingdom Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 275. United Kingdom Allergy Shots, by End User USD Million (2025-2030)
  • Table 276. Netherlands Allergy Shots, by Application USD Million (2025-2030)
  • Table 277. Netherlands Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 278. Netherlands Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 279. Netherlands Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 280. Netherlands Allergy Shots, by End User USD Million (2025-2030)
  • Table 281. Rest of Europe Allergy Shots, by Application USD Million (2025-2030)
  • Table 282. Rest of Europe Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 283. Rest of Europe Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 284. Rest of Europe Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 285. Rest of Europe Allergy Shots, by End User USD Million (2025-2030)
  • Table 286. MEA Allergy Shots, by Country USD Million (2025-2030)
  • Table 287. MEA Allergy Shots, by Application USD Million (2025-2030)
  • Table 288. MEA Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 289. MEA Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 290. MEA Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 291. MEA Allergy Shots, by End User USD Million (2025-2030)
  • Table 292. Middle East Allergy Shots, by Application USD Million (2025-2030)
  • Table 293. Middle East Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 294. Middle East Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 295. Middle East Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 296. Middle East Allergy Shots, by End User USD Million (2025-2030)
  • Table 297. Africa Allergy Shots, by Application USD Million (2025-2030)
  • Table 298. Africa Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 299. Africa Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 300. Africa Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 301. Africa Allergy Shots, by End User USD Million (2025-2030)
  • Table 302. North America Allergy Shots, by Country USD Million (2025-2030)
  • Table 303. North America Allergy Shots, by Application USD Million (2025-2030)
  • Table 304. North America Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 305. North America Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 306. North America Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 307. North America Allergy Shots, by End User USD Million (2025-2030)
  • Table 308. United States Allergy Shots, by Application USD Million (2025-2030)
  • Table 309. United States Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 310. United States Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 311. United States Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 312. United States Allergy Shots, by End User USD Million (2025-2030)
  • Table 313. Canada Allergy Shots, by Application USD Million (2025-2030)
  • Table 314. Canada Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 315. Canada Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 316. Canada Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 317. Canada Allergy Shots, by End User USD Million (2025-2030)
  • Table 318. Mexico Allergy Shots, by Application USD Million (2025-2030)
  • Table 319. Mexico Allergy Shots, by Therapy USD Million (2025-2030)
  • Table 320. Mexico Allergy Shots, by Allergy USD Million (2025-2030)
  • Table 321. Mexico Allergy Shots, by Distribution Channel USD Million (2025-2030)
  • Table 322. Mexico Allergy Shots, by End User USD Million (2025-2030)
  • Table 323. Research Programs/Design for This Report
  • Table 324. Key Data Information from Secondary Sources
  • Table 325. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Allergy Shots: by Application USD Million (2018-2023)
  • Figure 5. Global Allergy Shots: by Therapy USD Million (2018-2023)
  • Figure 6. Global Allergy Shots: by Allergy USD Million (2018-2023)
  • Figure 7. Global Allergy Shots: by Distribution Channel USD Million (2018-2023)
  • Figure 8. Global Allergy Shots: by End User USD Million (2018-2023)
  • Figure 9. South America Allergy Shots Share (%), by Country
  • Figure 10. Asia Pacific Allergy Shots Share (%), by Country
  • Figure 11. Europe Allergy Shots Share (%), by Country
  • Figure 12. MEA Allergy Shots Share (%), by Country
  • Figure 13. North America Allergy Shots Share (%), by Country
  • Figure 14. Global Allergy Shots share by Players 2023 (%)
  • Figure 15. Global Allergy Shots share by Players (Top 3) 2023(%)
  • Figure 16. Global Allergy Shots share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. ALK Abello (Denmark) Revenue, Net Income and Gross profit
  • Figure 19. ALK Abello (Denmark) Revenue: by Geography 2023
  • Figure 20. Stallergenes Greer (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. Stallergenes Greer (United Kingdom) Revenue: by Geography 2023
  • Figure 22. Allergy Therapeutics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. Allergy Therapeutics (United Kingdom) Revenue: by Geography 2023
  • Figure 24. Aimmune Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 25. Aimmune Therapeutics (United States) Revenue: by Geography 2023
  • Figure 26. Anergis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Anergis (Switzerland) Revenue: by Geography 2023
  • Figure 28. Arrayit Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 29. Arrayit Corporation (United States) Revenue: by Geography 2023
  • Figure 30. Biomay AG (Austria) Revenue, Net Income and Gross profit
  • Figure 31. Biomay AG (Austria) Revenue: by Geography 2023
  • Figure 32. HAL Allergy Group (Netherlands) Revenue, Net Income and Gross profit
  • Figure 33. HAL Allergy Group (Netherlands) Revenue: by Geography 2023
  • Figure 34. DBV Technologies (France) Revenue, Net Income and Gross profit
  • Figure 35. DBV Technologies (France) Revenue: by Geography 2023
  • Figure 36. Allergopharma GmbH & Co. KG (Dermapharm) (Germany) Revenue, Net Income and Gross profit
  • Figure 37. Allergopharma GmbH & Co. KG (Dermapharm) (Germany) Revenue: by Geography 2023
  • Figure 38. Global Allergy Shots: by Application USD Million (2025-2030)
  • Figure 39. Global Allergy Shots: by Therapy USD Million (2025-2030)
  • Figure 40. Global Allergy Shots: by Allergy USD Million (2025-2030)
  • Figure 41. Global Allergy Shots: by Distribution Channel USD Million (2025-2030)
  • Figure 42. Global Allergy Shots: by End User USD Million (2025-2030)
  • Figure 43. South America Allergy Shots Share (%), by Country
  • Figure 44. Asia Pacific Allergy Shots Share (%), by Country
  • Figure 45. Europe Allergy Shots Share (%), by Country
  • Figure 46. MEA Allergy Shots Share (%), by Country
  • Figure 47. North America Allergy Shots Share (%), by Country
List of companies from research coverage that are profiled in the study
  • ALK Abello (Denmark)
  • Stallergenes Greer (United Kingdom)
  • Allergy Therapeutics (United Kingdom)
  • Aimmune Therapeutics (United States)
  • Anergis (Switzerland)
  • Arrayit Corporation (United States)
  • Biomay AG (Austria)
  • HAL Allergy Group (Netherlands)
  • DBV Technologies (France)
  • Allergopharma GmbH & Co. KG (Dermapharm) (Germany)
Additional players considered in the study are as follows:
Jubilant Pharma Holdings Inc. (United States) , BioSpace (United States) , Omega Laboratories Limited (Canada) , Quantum Allergy (Canada) , Mylan (United States) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 210 Pages 73 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Allergy Shots Market Quantitative research analysis
Global Allergy Shots Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as ALK Abello (Denmark), Stallergenes Greer (United Kingdom), Allergy Therapeutics (United Kingdom), Aimmune Therapeutics (United States), Anergis (Switzerland), Arrayit Corporation (United States), Biomay AG (Austria), HAL Allergy Group (Netherlands), DBV Technologies (France) and Allergopharma GmbH & Co. KG (Dermapharm) (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Investments in Healthcare Infrastructure" is seen as one of major influencing trends for Allergy Shots Market during projected period 2023-2030.
The Allergy Shots market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Allergy Shots Market Report?

Have a Query? Click Here

Other Related Reports

Real Time PCR qPCR Comprehensive Study by Type (Real-Time PCR (qPCR) Systems, Reagents and Assays, Consumables, PCR Primers, Reagents, PCR Plates, Others), Application (Gene expression (mRNA) analysi...
$ 3750
Antimicrobial Hospital Curtains Comprehensive Study by Application (Hospitals, Ambulatory surgical centers, Private clinics, Emergency Centers, Nursing homes), Usage (Reusable, Disposable/Single Use)...
$ 3350
Optogenetics Actuators And Sensors Comprehensive Study by Type (Actuators (Channelrhodopsin, Halorhodopsin, and Archaerhodopsin), Sensors (Genetically Encoded Calcium Indicators, Voltage-Sensitive Fl...
$ 3750
Medical oxygen concentrators and oxygen cylinders Comprehensive Study by Type (Portable medical oxygen concentrators, Stationary medical oxygen concentrators, Oxygen cylinders), Application (Copd, As...
$ 3650
Nasal Tube Fastener Comprehensive Study by Type (Latex, Fabric, Other), Application (Hospitals, Clinics, Others), Packaging (Box, Case), End User (Infant, Pediatric, Adult) Players and Region - Globa...
$ 3600
Veterinary Orthopedic Devices Comprehensive Study by Type (Plates (Cuttable plates, Self-compression plates, Limited contact decompression plates, Reconstruction plates, T-plates with or without curv...
$ 3750